CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
体内 CAR-T 细胞在多发性骨髓瘤中实现深度缓解
英文原题：In Vivo CAR T Cells Deliver Deep Responses in Myeloma.
查看英文原题
In Vivo CAR T Cells Deliver Deep Responses in Myeloma.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
早期临床结果表明，体内T细胞工程可触发快速的嵌合抗原受体表达，并在复发性多发性骨髓瘤患者中诱导深度缓解——无需传统过继性细胞疗法所需的制造过程。然而，仍需更大规模的研究来确定现货型体内疗法与现有自体疗法相比如何。
展开英文摘要原文
Early clinical results show that inside-the-body T-cell engineering can trigger rapid chimeric antigen receptor expression and induce deep responses in patients with relapsed multiple myeloma-without the manufacturing required for conventional adoptive cell therapy. Larger studies are needed, however, to determine how off-the-shelf in vivo approaches compare with existing autologous therapies.
论文信息
- 期刊
- Cancer discovery2026 Feb 6
- 原文标识
- PubMed 41405215 · DOI 10.1158/2159-8290.CD-NW2025-0112